ClinicalTrials.gg
Active, not recruitingNCT06153966Updated Sep 18, 2026

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

A Phase 1/2 interventional study of ION717 and Placebo in Prion Disease, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 13 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.

Read the detailed description

This is a first-in-human, multi-center study in participants with prion disease. The study will consist of a screening period of up to 6 weeks, a 30-week treatment period, a 142-week open-label extension period and a 32-week post-treatment period. Multiple dose levels will be tested.

The trial consists of three Regimens. Participants in Regimens 1 and 2 received multiple doses of study drug (ION717 and placebo) during the 30-week double-blind treatment period; the order of doses (i.e. whether a given dose was ION717 or placebo) was blinded. Regimen 3 is open label.

02

Conditions studied

  • Prion Disease
03

In context

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • A confirmed diagnosis of probable or definite prion disease.
  • Early-stage prion disease at the time of Screening.
  • Willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits.
  • Patients must have a caregiver who is ≥ 18 years old and who is able and willing to facilitate the patient's involvement, to the best of their ability, for the duration of the trial; caregivers must also be able and willing to provide information about themselves and the patient for the duration of the trial.
  • Aged ≥ 18 at the time of .

Key Exclusion Criteria

  • abnormalities in medical history, laboratory tests or physical examination that would render a patient unsuitable for inclusion.
  • Any or unwillingness to undergo an MRI.
  • Obstructive hydrocephalus, presence of a functional ventriculoperitoneal shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter.
  • Known brain or spinal disease that would interfere with the LP process, CSF circulation or safety assessment.
  • Have any other condition, which, in the opinion of the Investigator would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    ION717 + Placebo, Regimen 1

    Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 142-week open-label extension period.

    Drug: ION717 · Drug: Placebo

  • Experimental
    ION717 + Placebo, Regimen 2

    Participants will receive multiple doses of study drug (ION717 and placebo) during the 30-week treatment period; the order of doses is blinded. Participants will then receive multiple doses of ION717 during the 142-week open-label extension period.

    Drug: ION717 · Drug: Placebo

  • Experimental
    ION717, Regimen 3

    Participants will receive multiple doses of ION717 during the 30-week treatment period and the 142-week open-label extension period.

    Drug: ION717

Interventions

  • DrugION717

    ION717 will be administered by IT injection.

  • DrugPlacebo

    Placebo-matching ION717 will be administered by IT injection.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events.

    Time frame: Baseline up to Week 33

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ION717

    Time frame: on Day 1 and Week 9

  2. Area Under the Plasma Concentration-time Curve (AUC) of ION717

    Time frame: on Day 1 and Week 9

  3. Half-life (t1/2λz) of ION717 in Plasma

    Time frame: on Day 1 and Week 9

  4. Cerebrospinal fluid (CSF) Concentration of ION717

    Time frame: Pre-dose and at multiple points post-dose up to Week 33

  5. Amount of ION717 Excreted in Urine

    Time frame: Post-dose on Day 1

  6. Percent Change from Baseline in Prion Protein (PrP) Concentration in CSF

    Time frame: Pre-dose and at multiple points post-dose up to Week 33

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Dec 1, 2023
StartActual
Jan 4, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153966
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Jan 4, 2024
Primary completion
Apr 2027 (estimated)
Completion
Aug 2030 (estimated)
Last update
Sep 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion